Loading
Pumitamig / Relapsed/refractory Small Cell Lung Cancer / BMS-986525 · Phase 1/2 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 1/2 trial of BMS-986525 alone and combined with Pumitamig in relapsed/refractory small cell lung cancer, currently recruiting. No efficacy or safety results are reported in this registry record; the trial is designed to assess safety, tolerability, dose-limiting toxicity, and adverse event-related discontinuations over approximately 2 years of follow-up.
Phase 1/2, Interventional, Non Randomized, Parallel, Open label, Treatment purpose. Relapsed/Refractory Small Cell Lung Cancer; age from 18 Years. Intervention: Part 1A: BMS-986525 Monotherapy Dose Escalation; Part 2A: BMS-986525 Monotherapy Dose Expansion; Part 1B: BMS-986525 Combination with Pumitamig Dose Escalat…; Part 2B: BMS-986525 Combination with Pumitamig Dose Expansi…. n = 240. 13 sites across 6 countries.
This is a registered Phase 1/2 trial of BMS-986525 alone and combined with Pumitamig in relapsed/refractory small cell lung cancer, currently recruiting. No efficacy or safety results are reported in this registry record; the trial is designed to assess safety, tolerability, dose-limiting toxicity, and adverse event-related discontinuations over approximately 2 years of follow-up.
No results, safety data, or efficacy outcomes are reported in this registry record.
This trial is in early recruitment and has not yet reported safety or efficacy data. Clinicians should monitor for future publications or trial completion summaries to inform use of BMS-986525 and the combination regimen.
Phase 1/2 safety and tolerability trial in an active recruitment phase with no results posted; this is a planned study registration documenting trial design and safety endpoints only.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in early recruitment and has not yet reported safety or efficacy data. Clinicians should monitor for future publications or trial completion summaries to inform use of BMS-986525 and the combination regimen.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07325136). This is a study registration, not published results. Lead sponsor: Bristol-Myers Squibb. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 240 participants (ESTIMATED). Conditions: Relapsed/Refractory Small Cell Lung Cancer. Interventions: DRUG: BMS-986525; DRUG: Pumitamig. Primary outcome measures: Number of participants with adverse events (AEs) , Up to approximately 2 years; Number of participants with serious adverse events (SAEs) , Up to approximately 2 years; Number of participants with AEs meeting dose-limiting toxicity (DLT) criteria , Up to 21 days; Number of participants with AEs leading to discontinuation , Up to approximately 2 years; Number of participants with AEs leading to death , Up to approximately 2 years. Brief summary: The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.